Ono Pharmaceutical Co., Ltd. (OPHLY) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Drug Manufacturers - General Branche. Der Hauptsitz des Unternehmens ist in Osaka, Japan. Der aktuelle CEO ist Gyo Sagara.
OPHLY hat IPO-Datum 2012-10-02, 3,853 Vollzeitbeschäftigte, gelistet an der Other OTC, eine Marktkapitalisierung von $7.32B.
Ono Pharmaceutical Co., Ltd. is a Japan-based pharmaceutical company headquartered in Osaka with a history dating back to 1717. The company develops, manufactures, and markets a diverse portfolio of prescription medications across oncology, cardiovascular, immunology, and other therapeutic areas, with leading products including OPDIVO for cancer treatment, FORXIGA for diabetes, ORENCIA for rheumatoid arthritis, and CORALAN for heart failure. Operating globally through its subsidiaries, Ono maintains a robust pipeline of drugs in development targeting a wide range of cancers, neurological disorders, autoimmune conditions, and other serious diseases. The company combines its heritage in pharmaceutical innovation with modern research capabilities to serve patients and healthcare systems worldwide.
